 Mr. Democko brings over 20 years of regulatory affairs experience in the development of both biologics and small molecules ranging from pre-IND through commercial stage companies across several therapeutic areas. Mr. Democko will lead the regulatory efforts for the Companys rare hematologic and systemic complement-mediated disorders portfolio. 